=== PAGE 2 ===

COMPLETE PAGE ANALYSIS:
--------------------------------------------------
Here is the extracted text content from the PDF page, preserving its original layout and structure:

                                                                        WARNING: SEVERE TOXIC REACTIONS, INCLUDING EMBRYO-FETAL TOXICITY
                                                                                     See full prescribing information for complete boxed warning.

        Methotrexate can cause the following severe or fatal adverse reactions.
        Monitor closely and modify dose or discontinue methotrexate as appropriate.

        • Bone marrow suppression [see Warnings and Precautions (5.1)]
        • Serious infections [see Warnings and Precautions (5.2)]
        • Renal toxicity and increased toxicity with renal impairment [see Warnings and Precautions (5.3)]
        • Gastrointestinal toxicity [see Warnings and Precautions (5.4)]
        • Hepatic toxicity [see Warnings and Precautions (5.5)]
        • Pulmonary toxicity [see Warnings and Precautions (5.6)]
        • Hypersensitivity and dermatologic reactions [see Warnings and Precautions (5.7)]
        • Methotrexate can cause embryo-fetal toxicity, including fetal death. Use in pJIA is contraindicated in
           pregnancy. Counsel the benefits and risks of XATMEP and risks to the fetus when prescribing XATMEP to a
           pregnant patient with a neoplastic disease. Advise females and males of reproductive potential to use
           effective contraception during and after treatment with XATMEP [see Contraindications (4), Warnings and
           Precautions (5.8), Use in Specific Populations (8.1, 8.3)].


INDICATIONS

Xatmep is a folate analog metabolic inhibitor indicated for the:

       •     treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a multi-phase, combination
             chemotherapy maintenance regimen.

       •     management of pediatric patients with active polyarticular juvenile idiopathic arthritis (pJIA) who have had an
             insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose non-
             steroidal anti-inflammatory agents (NSAIDs).


For Full Prescribing Information of Xatmep, please click here: Full Prescribing Information

For more information on Xatmep, please click here: Xatmep Website


XTM-27

Azurity Pharmaceuticals | 841 Woburn St., Wilmington, MA 01887 | Azurity.com


© 2020 Azurity Pharmaceuticals™ Inc. All rights reserved.
Azurity Pharmaceuticals™, Inc. is the parent company of Silvergate Pharmaceuticals, Inc. Labeling may reflect either name.


UNSUBSCRIBE   |   PRIVACY   |   CONTACT US
